Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Immune Thrombocytopenia Associated with Hepatitis A Infection in Children

Hepatitis A infection is usually a self–limited disease during childhood. Autoimmune manifestations are rarely reported among patients with HA infection. We describe a previously healthy 6-yr-old male with acute hepatitis A who developed immune thrombocytopenia.

متن کامل

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab

Fig. 1. Platelet count after alemtuzumab treatment. Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab TO THE EDITOR: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by an isolated decrease in platelet count. There are multiple mechanisms underlying this disease, including autoantibodies against platelet membrane proteins and impaired p...

متن کامل

immune thrombocytopenia associated with hepatitis a infection in children

hepatitis a infection is usually a self–limited disease during childhood. autoimmune manifestations are rarely reported among patients with ha infection. we describe a previously healthy 6-yr-old male with acute hepatitis a who developed immune thrombocytopenia.

متن کامل

Bullous pemphigoid associated with acquired hemophilia

daily for 1 week), pulse therapy with methylprednisolone (1000 mg/day for 3 days) and rituximab (100 mg/week for 2 weeks) were initially used for correcting the coagulopathy. Prednisolone (1 mg/kg/day) and cyclophosphamide (100 mg/ day) were prescribed as maintenance therapy. The coagulatory disorder improved after 2 months of treatment associated with reduction of factor VIII inhibitor to 35 B...

متن کامل

Acquired hemophilia A: emerging treatment options

Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor) to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe, potentially life-threatening hemorrhage. Disease management focuses on controlling bleeding, primarily with the use of bypassing therapy and recombinant porcine FVIII, and permanently eradicating the autoantibody ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Medicine

سال: 2018

ISSN: 0025-7974

DOI: 10.1097/md.0000000000012044